Voloridge Investment Management’s Ocular Therapeutix OCUL Stock Holding History

Voloridge Investment Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-812,078	Closed	-$9.86M	–	1202
2025 Q4	$9.86M	Buy	+812,078	New	+$9.86M	0.03%	584
2025 Q2	–	Sell	-45,437	Closed	-$333K	–	1304
2025 Q1	$333K	Buy	45,437 +11,954	+36%	+$91.9K	﹤0.01%	1119
2024 Q4	$286K	Sell	33,483 -83,499	-71%	-$815K	﹤0.01%	1128
2024 Q3	$1.02M	Sell	116,982 -572,035	-83%	-$4.71M	﹤0.01%	1021
2024 Q2	$4.71M	Sell	689,017 -397,777	-37%	-$2.46M	0.02%	763
2024 Q1	$9.89M	Buy	+1,086,794	New	+$7.71M	0.04%	494
2022 Q2	–	Sell	-174,967	Closed	-$866K	–	1572
2022 Q1	$866K	Sell	174,967 -134,750	-44%	-$747K	﹤0.01%	1160
2021 Q4	$2.16M	Buy	309,717 +242,211	+359%	+$1.88M	0.01%	1044
2021 Q3	$675K	Buy	+67,506	New	+$758K	﹤0.01%	1390
2021 Q1	–	Sell	-24,060	Closed	-$498K	–	1578
2020 Q4	$498K	Buy	+24,060	New	+$357K	﹤0.01%	1125

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Voloridge Investment Management's OCUL Position: Q1 2026 in Review

Voloridge Investment Management sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 812,078 shares — an estimated $9.86M sold.

Voloridge Investment Management first reported a position in OCUL in Q4 2020 and held it in 10 quarters. The position peaked at $9.89M in Q1 2024. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Voloridge Investment Management reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Voloridge Investment Management sold 812,078 Ocular Therapeutix shares in Q1 2026, an estimated $9.86M.
Voloridge Investment Management first reported a position in Ocular Therapeutix in Q4 2020 and held it in 10 quarters.
Voloridge Investment Management's Ocular Therapeutix position peaked at $9.89M in Q1 2024.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.